Literature DB >> 7363446

A prospective national study of the safety of immunotherapy.

D Vervloet, E Khairallah, A Arnaud, J Charpin.   

Abstract

A prospective study was made in France to determine the frequency, nature, causes and consequences of systemic reactions occurring during specific immunotherapy. One hundred and fifty five reactions were recorded in 151, 997, injections given to 19,739 patients; a percentage of 0.1. It was higher with pollen extracts (0.2%) and practically nil with other extracts (house dust, Dermatophagoides, insect body, bacteria). Asthma, spasmodic rhinitis and urticaria were the most frequent, 80% of systemic reactions. In 59% no explanation could be found. The main known causes of adverse reactions were excessive doses of antigen, improper timing of treatment or incorrect technique of injection. After appropriate treatment the immunotherapy was continued in nearly 90% of the cases. Specific immunotherapy with the majority of extracts now being used, namely adsorbed extracts, is not dangerous but it must be precisely and cautiously done because errors are responsible for nearly 50% of the recorded systemic reactions.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7363446     DOI: 10.1111/j.1365-2222.1980.tb02080.x

Source DB:  PubMed          Journal:  Clin Allergy        ISSN: 0009-9090


  9 in total

Review 1.  Allergic emergencies in the emergency room.

Authors:  F Staikowsky; C Zanker; L Casenove
Journal:  Clin Rev Allergy Immunol       Date:  1999       Impact factor: 8.667

Review 2.  Standardized extracts, dust mite, and other arthropods (inhalants).

Authors:  A W Ford; T A Platts-Mills
Journal:  Clin Rev Allergy       Date:  1987-02

3.  Hyposensitisation.

Authors:  J O Warner; J W Kerr
Journal:  Br Med J (Clin Res Ed)       Date:  1987-05-09

Review 4.  Immunotherapy in allergic respiratory diseases.

Authors:  D Vervloet; X van der Brempt; D Charpin; J Birnbaum
Journal:  Lung       Date:  1990       Impact factor: 2.584

5.  Immunotherapy in respiratory allergy.

Authors:  R J Davies
Journal:  Thorax       Date:  1983-06       Impact factor: 9.139

Review 6.  Hyposensitization in asthma: a review.

Authors:  J O Warner
Journal:  J R Soc Med       Date:  1981-01       Impact factor: 5.344

Review 7.  Minimising the risks of allergen-specific injection immunotherapy.

Authors:  H J Malling
Journal:  Drug Saf       Date:  2000-10       Impact factor: 5.606

8.  Side effects of desensitization for allergy--a general practice survey.

Authors:  D A Rands; R C Godfrey
Journal:  J R Coll Gen Pract       Date:  1983-10

Review 9.  Safety considerations in assessing the role of immunotherapy in allergic disorders.

Authors:  J Bousquet; F B Michel
Journal:  Drug Saf       Date:  1994-01       Impact factor: 5.606

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.